MA41011B1 - Indazoles substitués, procédé de leur péparation, compositions pharmaceutiques les contenant, et leur utilisation pour la préparation des médicaments - Google Patents

Indazoles substitués, procédé de leur péparation, compositions pharmaceutiques les contenant, et leur utilisation pour la préparation des médicaments

Info

Publication number
MA41011B1
MA41011B1 MA41011A MA41011A MA41011B1 MA 41011 B1 MA41011 B1 MA 41011B1 MA 41011 A MA41011 A MA 41011A MA 41011 A MA41011 A MA 41011A MA 41011 B1 MA41011 B1 MA 41011B1
Authority
MA
Morocco
Prior art keywords
preparation
medicaments
endometriosis
prophylaxis
treatment
Prior art date
Application number
MA41011A
Other languages
English (en)
Inventor
Ulrich Bothe
Ulf Bömer
Reinhard Nubbemeyer
Christian Stegmann
Holger Siebeneicher
Nicole Schmidt
Judith Günther
Holger Steuber
Martin Lange
Andreas Sutter
Alexandra Rausch
Peter Hauff
Christian Friedrich
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA41011B1 publication Critical patent/MA41011B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne de nouveaux indazoles substitués, un procédé pour leur préparation, leur utilisation seuls ou en combinaison pour le traitement et/ou la prophylaxie de maladies ainsi que leur utilisation pour la production de médicaments destinés au traitement et/ou à la prophylaxie de maladies, en particulier pour le traitement et/ou la prophylaxie de l'endométriose ainsi que des douleurs associée à l'endométriose et d'autres symptômes associés à l'endométriose tels que la dysménorrhée, la dyspareunie, la dysurie et la dyschésie, les lymphomes, la polyarthrite rhumatoïde, les spondylarthropathies (en particulier la spondylarthrite psoriasique et la spondylarthrite ankylosante), le lupus érythémateux, la sclérose en plaques, la dégénérescence maculaire, la bpco, la goutte, les maladies de la stéatose du foie, la résistance à l'insuline, les maladies tumorales et le psoriasis.
MA41011A 2014-11-26 2015-11-25 Indazoles substitués, procédé de leur péparation, compositions pharmaceutiques les contenant, et leur utilisation pour la préparation des médicaments MA41011B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195032 2014-11-26
PCT/EP2015/077596 WO2016083433A1 (fr) 2014-11-26 2015-11-25 Nouveaux indazoles substitués, procédé pour leur préparation, préparations pharmaceutiques contenant ceux-ci et leur utilisation pour produire des médicaments

Publications (1)

Publication Number Publication Date
MA41011B1 true MA41011B1 (fr) 2020-08-31

Family

ID=51982455

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41011A MA41011B1 (fr) 2014-11-26 2015-11-25 Indazoles substitués, procédé de leur péparation, compositions pharmaceutiques les contenant, et leur utilisation pour la préparation des médicaments

Country Status (42)

Country Link
US (6) US10308634B2 (fr)
EP (3) EP3674298B9 (fr)
JP (1) JP6496823B2 (fr)
KR (1) KR102083857B1 (fr)
CN (2) CN107406416B (fr)
AR (1) AR102827A1 (fr)
AU (2) AU2015352603B2 (fr)
BR (2) BR112017011005B1 (fr)
CA (1) CA2968614C (fr)
CL (1) CL2017001364A1 (fr)
CO (1) CO2017005374A2 (fr)
CR (1) CR20170220A (fr)
CU (1) CU24448B1 (fr)
CY (1) CY1123815T1 (fr)
DK (2) DK3224254T3 (fr)
DO (1) DOP2017000127A (fr)
EA (1) EA032509B1 (fr)
EC (1) ECSP17032530A (fr)
ES (2) ES2976932T3 (fr)
FI (1) FI3674298T3 (fr)
HR (2) HRP20200974T1 (fr)
HU (2) HUE049341T2 (fr)
IL (3) IL252185B (fr)
JO (1) JO3705B1 (fr)
LT (2) LT3224254T (fr)
MA (1) MA41011B1 (fr)
ME (1) ME03745B (fr)
MX (2) MX390119B (fr)
NI (1) NI201700063A (fr)
NZ (1) NZ732126A (fr)
PE (1) PE20171376A1 (fr)
PH (1) PH12017500972A1 (fr)
PL (2) PL3674298T3 (fr)
PT (2) PT3224254T (fr)
RS (2) RS65327B1 (fr)
SG (3) SG10201903474PA (fr)
SI (2) SI3674298T1 (fr)
TN (1) TN2017000226A1 (fr)
TW (2) TWI689502B (fr)
UA (2) UA123813C2 (fr)
UY (1) UY36411A (fr)
WO (1) WO2016083433A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) * 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
EP3195865A1 (fr) * 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Combinaisons d'inhibiteurs d'irak4 et inhibiteurs de btk
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
EP3423446B1 (fr) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Nouveaux indazoles substitués en 2, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour produire des médicaments
EP3219329A1 (fr) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
KR102409105B1 (ko) * 2016-04-29 2022-06-16 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
UA123169C2 (uk) * 2016-04-29 2021-02-24 Байєр Фарма Акцієнгезелльшафт Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
EA035867B1 (ru) * 2016-04-29 2020-08-24 Байер Фарма Акциенгезельшафт Синтез индазолов
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
UA125650C2 (uk) 2016-09-09 2022-05-11 Інсайт Корпорейшн Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
TW201811799A (zh) 2016-09-09 2018-04-01 美商英塞特公司 吡唑并嘧啶化合物及其用途
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018060072A1 (fr) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Nouveaux benzimidazoles substitués, leur procédé de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la production de médicaments
US20180228786A1 (en) 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
DK3600270T3 (da) 2017-03-31 2023-07-10 Aurigene Oncology Ltd Forbindelser og sammensætninger til behandling af hæmatologiske lidelser
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
IL272575B2 (en) 2017-08-16 2023-09-01 Univ Vanderbilt Indazole compounds as allosteric enhancers of mglur4, compositions and methods for treating neurological dysfunction
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US10800761B2 (en) 2018-02-20 2020-10-13 Incyte Corporation Carboxamide compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
JP7456948B2 (ja) 2018-06-27 2024-03-27 エフ． ホフマン－ラ ロシュ アーゲー 放射性標識カンナビノイド受容体２リガンド
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
WO2020035019A1 (fr) * 2018-08-17 2020-02-20 浙江海正药业股份有限公司 Dérivé d'indazole amine, son procédé de préparation et son utilisation médicale
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
EP3889150A4 (fr) * 2018-12-25 2022-02-23 Shanghai Meiyue Biotech Development Co., Ltd. Composé servant d'inhibiteur d'irak
CN111362920B (zh) * 2018-12-25 2024-06-07 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111499612B (zh) * 2019-01-30 2022-12-30 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
CN111560012B (zh) * 2019-02-14 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物
CN111793064B (zh) * 2019-04-02 2023-06-23 上海美悦生物科技发展有限公司 一种作为irak抑制剂的化合物及其制备方法和用途
WO2020259626A1 (fr) * 2019-06-26 2020-12-30 南京明德新药研发有限公司 Composé imidazopyridine utilisé en tant qu'inhibiteur d'irak4
JP2022539374A (ja) * 2019-06-27 2022-09-08 バイオジェン・エムエイ・インコーポレイテッド ２ｈ－インダゾール誘導体及び疾患の処置におけるそれらの使用
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
WO2021007477A1 (fr) 2019-07-11 2021-01-14 E-Scape Bio, Inc. Indazoles et azaindazoles en tant qu'inhibiteurs de lrrk2
MX2022001562A (es) 2019-08-06 2022-04-26 Incyte Corp Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
US20220298139A1 (en) * 2019-09-24 2022-09-22 Shanghai Meiyue Biotech Development Co., Ltd. Irak inhibitor and preparation method therefor and use thereof
CN111072634B (zh) * 2020-01-03 2022-07-22 中国医科大学 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
US11866405B2 (en) 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CN113278017B (zh) * 2021-05-27 2023-03-28 上海应用技术大学 取代吲唑类化合物、制备方法、应用和包含其的组合物
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
WO2023283372A1 (fr) * 2021-07-07 2023-01-12 Biogen Ma Inc. Composés pour le ciblage de la dégradation de protéines irak4
WO2023098857A1 (fr) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Inhibiteur d'irak et son utilisation
CN119894895A (zh) 2022-11-04 2025-04-25 领泰生物医药(绍兴)有限公司 Irak4降解剂及其用途
EP4618984A1 (fr) * 2022-11-17 2025-09-24 Elanco Animal Health GmbH Procédés et compositions pour lutter contre la douleur et l'inflammation
CN116120283B (zh) * 2022-12-13 2025-01-28 药康众拓(北京)医药科技有限公司 一种氘代啶酰胺类irak-4抑制剂药物及用途
KR20250004525A (ko) * 2023-06-29 2025-01-08 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246606B1 (es) 2002-07-23 2007-06-01 Izar Construcciones Navales S.A. Unidad semi-sumergible auto-propulsada para transporte y engorde de peces vivos.
CA2493026C (fr) * 2002-07-31 2011-05-24 Bayer Schering Pharma Aktiengesellschaft Anthranylamidopyrimidines inhibant vegfr-2 et vegfr-3
ATE500216T1 (de) 2003-06-25 2011-03-15 Je Il Pharmaceutical Co Ltd Tricyclische derivate oder pharmazeutisch unnbedenkliche salze davon, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
WO2005082866A2 (fr) 2004-02-20 2005-09-09 Pfizer Limited Derives de triazole substitues utilises en tant qu'antagonistes de l'oxytocine
WO2006061715A2 (fr) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Derives de methylene
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
US20100048660A1 (en) 2006-02-10 2010-02-25 Graham Michael Wynne Treatment of duchenne muscular dystrophy
TWI435863B (zh) 2006-03-20 2014-05-01 Nihon Nohyaku Co Ltd Ｎ-２-（雜）芳基乙基甲醯胺衍生物及含該衍生物之蟲害防治劑
US7879887B2 (en) 2006-06-29 2011-02-01 Nissan Chemical Industries, Ltd. α-amino acid derivatives and medicaments containing the same as an active ingredient
KR20090049076A (ko) * 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
FR2917735B1 (fr) 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
WO2009117421A2 (fr) 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
EP2507226A1 (fr) 2009-12-03 2012-10-10 Glaxo Group Limited Nouveaux composés
WO2011153588A1 (fr) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Inhibiteurs de polymérase virale
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
BR112013020270A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag derivados de pirazol microbicidas
EP2489663A1 (fr) 2011-02-16 2012-08-22 Almirall, S.A. Composés en tant qu'inhibiteurs de la syk kinase
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
WO2013106254A1 (fr) 2012-01-11 2013-07-18 Dow Agrosciences Llc Compositions pesticides et procédés qui leur sont associés
EP2852596B1 (fr) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP2015002717A (ja) 2013-06-21 2015-01-08 住友ベークライト株式会社 蓋付き容器
TWI667233B (zh) * 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
SG11201605408RA (en) * 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
JP2017518348A (ja) 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
UY36660A (es) 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
EP3423446B1 (fr) 2016-03-03 2020-09-16 Bayer Pharma Aktiengesellschaft Nouveaux indazoles substitués en 2, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour produire des médicaments
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
KR102409105B1 (ko) 2016-04-29 2022-06-16 바이엘 파마 악티엔게젤샤프트 인다졸의 합성
UA123169C2 (uk) 2016-04-29 2021-02-24 Байєр Фарма Акцієнгезелльшафт Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду
MY199070A (en) 2016-06-01 2023-10-12 Bayer Pharma AG Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals
SG10202011653WA (en) 2016-06-01 2020-12-30 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Also Published As

Publication number Publication date
US12006303B2 (en) 2024-06-11
AU2015352603B2 (en) 2020-04-02
IL269444B (en) 2020-07-30
BR112017011005A2 (pt) 2019-05-14
SG10201903475TA (en) 2019-05-30
EP3224254B1 (fr) 2020-04-15
ES2976932T3 (es) 2024-08-13
PE20171376A1 (es) 2017-09-15
PH12017500972A1 (en) 2017-12-18
US20230174508A1 (en) 2023-06-08
PL3224254T3 (pl) 2020-09-21
EP3224254A1 (fr) 2017-10-04
SG11201704092YA (en) 2017-06-29
AU2020200979A1 (en) 2020-02-27
SI3224254T1 (sl) 2020-07-31
LT3674298T (lt) 2024-04-10
ES2976932T9 (es) 2024-09-05
CA2968614C (fr) 2019-10-29
PT3224254T (pt) 2020-06-17
SG10201903474PA (en) 2019-05-30
TWI689502B (zh) 2020-04-01
JP6496823B2 (ja) 2019-04-10
US20170349570A1 (en) 2017-12-07
EP4260909A3 (fr) 2024-03-20
IL269444A (en) 2019-11-28
IL252185B (en) 2019-10-31
RS60284B1 (sr) 2020-06-30
MX390119B (es) 2025-03-20
UA123813C2 (uk) 2021-06-02
BR112017011005B1 (pt) 2023-03-14
CN107406416B (zh) 2020-04-21
US12006304B2 (en) 2024-06-11
CU24448B1 (es) 2019-10-04
HRP20200974T1 (hr) 2020-10-02
US12559473B2 (en) 2026-02-24
CA2968614A1 (fr) 2016-06-02
NZ732126A (en) 2018-09-28
UY36411A (es) 2016-06-30
IL267537B (en) 2020-07-30
EP3674298B1 (fr) 2024-01-10
CO2017005374A2 (es) 2017-08-31
KR20170085590A (ko) 2017-07-24
NI201700063A (es) 2017-07-17
US20210053941A1 (en) 2021-02-25
JP2017535585A (ja) 2017-11-30
JO3705B1 (ar) 2021-01-31
CN110305109B (zh) 2022-04-08
CN110305109A (zh) 2019-10-08
SI3674298T1 (sl) 2024-05-31
BR122021002613B1 (pt) 2023-04-11
MX2017006910A (es) 2017-08-15
EA032509B1 (ru) 2019-06-28
EP3674298A1 (fr) 2020-07-01
HUE065938T2 (hu) 2024-06-28
ECSP17032530A (es) 2017-06-30
EP3674298B9 (fr) 2024-06-19
EP4260909A2 (fr) 2023-10-18
LT3224254T (lt) 2020-06-10
US20250034111A1 (en) 2025-01-30
UA120948C2 (uk) 2020-03-10
TW201629037A (zh) 2016-08-16
FI3674298T3 (fi) 2024-04-17
US20190233395A1 (en) 2019-08-01
US20220388982A1 (en) 2022-12-08
AU2015352603A1 (en) 2017-06-01
RS65327B1 (sr) 2024-04-30
CR20170220A (es) 2017-10-31
ES2796285T3 (es) 2020-11-26
WO2016083433A1 (fr) 2016-06-02
IL267537A (en) 2019-08-29
CL2017001364A1 (es) 2017-12-15
EA201791137A1 (ru) 2017-11-30
TWI717061B (zh) 2021-01-21
CY1123815T1 (el) 2022-03-24
DK3224254T3 (da) 2020-07-13
TN2017000226A1 (en) 2018-10-19
MX2020010623A (es) 2022-02-16
ME03745B (fr) 2021-04-20
AU2020200979B2 (en) 2021-01-07
IL252185A0 (en) 2017-07-31
PT3674298T (pt) 2024-04-01
PL3674298T3 (pl) 2024-06-24
CU20170073A7 (es) 2017-10-05
KR102083857B1 (ko) 2020-03-03
MX380150B (es) 2025-03-12
US10308634B2 (en) 2019-06-04
HRP20240414T1 (hr) 2024-06-21
CN107406416A (zh) 2017-11-28
AR102827A1 (es) 2017-03-29
DK3674298T3 (da) 2024-04-08
HUE049341T2 (hu) 2020-09-28
DOP2017000127A (es) 2017-07-31
US10793545B2 (en) 2020-10-06
TW202002973A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
MA41011B1 (fr) Indazoles substitués, procédé de leur péparation, compositions pharmaceutiques les contenant, et leur utilisation pour la préparation des médicaments
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
ZA202403426B (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
Luo et al. Dermatomyositis, polymyositis and immune-mediated necrotising myopathies
TN2017000181A1 (en) Pharmaceutical products and stable liquid compositions of il-17 antibodies
EA202190927A1 (ru) Иммуноаблативные виды терапии
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
BR112017022008A2 (pt) composições de di-hidropiridoisoquinolinonas e composições farmacêuticas das mesmas para o tratamento de transtornos inflamatórios
MA38837B1 (fr) Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique
PH12017501473A1 (en) Novel proteins specific for pyoverdine and pyochelin
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
JO3327B1 (ar) تركيبات قرص تحتوي على المركب (z)- 2- سيانو- 3- هيدروكسي- بيوت- 2- حمض ينويك- (4'- ثالث فلورو مثيل فنيل)- أميد بمستوى ثبات محسن
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
EA201700042A1 (ru) Соединения имидазопиридазина
EA201891710A1 (ru) Терапевтические соединения
JOP20170134A1 (ar) مركبات بينزيميدازول مستبدلة جديدة، عمليات لتحضيرها، مستحضرات صيدلية تشملها واستخدامها لتحضير الأدوية
TN2017000547A1 (en) Fusion molecules
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
WO2019025993A3 (fr) Composition médicinale d'origine amarante pour traitement cardiovasculaire
GB2519470A (en) Bicyclic aza compounds as muscarinic M1 receptor agonists
CR20220173A (es) Composición farmacéutica de extractos de plantas para tratar fibromialgia, artritis reumatoide, lupus y otras enfermedades autoinmunes
MA38849A1 (fr) Nouveaux composés d'indazole pour le traitement du diabete et leur procede de preparation
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c